Mr K K Tong is the Chief Executive Officer of New Frontier Health (Hong Kong) and the Executive Vice Secretary-General of the New Frontier Greater Bay Area Medical Executive Committee. He is responsible for overseeing the group's medical operations in Hong Kong, which include the Hong Kong Integrated Oncology Centre, Heal Oncology Centre, Heal Medical Centre, Hong Kong Integrated Diagnostic Imaging Centre, and Hong Kong Adventist Hospital Oncology Centre.

With over 20 years of experience in the pharmaceutical industry, Mr Tong has held key positions at multinational companies such as GlaxoSmithKline and UCB, managing marketing operations across various Asian markets, including Taiwan region, South Korea, and other ASEAN countries. Prior to joining the Hong Kong Integrated Oncology Centre in October 2018, he served as the General Manager for Hong Kong SAR and Macau SAR at Amgen, the world's largest independent biotechnology company, where he led the establishment of Amgen's Hong Kong SAR branch and was responsible for strategic decision-making and operational management.

Mr Tong has actively contributed to the advancement of innovative healthcare in the medical community. Since 2019, he has been the founding director of the Hong Kong Society for Innovative Medicine and served as a visiting lecturer at the Polytechnic University of Hong Kong's School of Professional and Continuing Education.

Mr Tong holds a degree in Biochemistry from The Chinese University of Hong Kong and a Master's degree in Health Services Management from The Hong Kong Polytechnic University, as well as a Master's degree in Data Science and Business Statistics from The Chinese University of Hong Kong.

Synopsis

Connecting Care to Conquer Hong Kong’s Healthcare Challenges

Hong Kong’s healthcare system is facing rapidly rising costs, driven by medical advances, population ageing, and workforce shortages. To address these pressures, New Frontier Group has built an integrated cancer-care ecosystem spanning home care, specialty day centres, Greater Bay Area hospitals, and the distribution of innovative Mainland drugs. This ecosystem helps relieve pressure on public hospitals, reduce the burden on patients and carers, improve clinical outcomes, and expand access to clinical trials.